

ACCELERATE IMMUNO-ONCOLOGY DRUG DISCOVERY & DEVELOPMENT

Robust & Reproducible Cell-Based Assays for Potency Testing

TIME-TO-MARKET IS CRITICAL!

Fast-track your immuno-oncology (IO) drug discovery & development with physiologically relevant cell-based assays

Eurofins DiscoverX offers the most comprehensive portfolio of cell-based assays to enable fast, effective, and clinically relevant understanding of IO to interrogate targets, pathways, and mechanisms to empower quicker development of IO therapeutics.

- **MOA-Reflective, Robust Assays** – Designed for regulatory acceptance, these assays are intended to interrogate specific target biology for fast implementation for discovery, validation, and characterization
- **Ready-To-Use Bioassay Format** – Highly reproducible and robust assay performance for seamless implementation in QC lot release programs
- **Broad Coverage of Checkpoint Modulators** – Industry's most comprehensive menu of stable cell lines and ready-to-use bioassays for targets including PD-1, SIRP α , CTLA4, OX40, ICOS, and others
- **Cytotoxicity Assays** – Specifically measure direct target cell death in co-cultures using relevant immune effector cells with KILR[®] cytotoxicity assays for ADCC, ADCP, CAR-T, T-cell redirection, and adoptive T-cell therapy

MULTIPLE ASSAY FORMATS TO ASSESS YOUR IO THERAPEUTIC MODALITY


Whether you are developing small molecule or biologic therapeutics, Eurofins DiscoverX provides you with a variety of drug discovery and development products based on the Enzyme Fragment Complementation platform for multiple applications to meet your specific IO research needs.

EFC (Enzyme Fragment Complementation);
ED (Enzyme Donor); EA (Enzyme Acceptor).



For more information on Immuno-Oncology assays, please visit

discoverX.com/IO



CELL-BASED ASSAYS FOR IO DRUG DISCOVERY & DEVELOPMENT

KILR® CYTOTOXICITY ASSAYS – EFFECTOR CELLS, BIOASSAYS, CELL LINES, RETROPARTICLES, AND CELL POOLS

Products	KILR Cell Line and Cell Pool Backgrounds							
KILR CD16 Effector Cells	4T1	COLO-205	HepG2	MCF7	PANC-1	SK-MEL-28	U2OS	
KILR Raji, Daudi, & NCI-N87 ADCC & ADCP Bioassay Kits	A498	Daudi	HL-60	MDA-MB	Raji	SKOV3	WIL2-S	
KILR ARH-77; Jurkat PD-1, LAG3 or TIM3; & U2OS EGFR, PD-L1, or PD-L2 Cell Lines	A549	DU-145	HT-108	MM-1R	Ramos	SR		
KILR Retroparticles for Adherent & Suspension Cells	ARH-77	EL4	Hut78	MOLT-4	RPMI 8226	T2		
KILR Cell Pools in Various Cell Backgrounds	BT-474	H322	Jurkat	NCI-H292	SKBR3	THP-1		
	CCRF-CEM	HCT-116	K562	NCI-N87	SK-MEL-5	U118-M		

CHECKPOINT RECEPTOR ASSAYS – BIOASSAYS AND CELL LINES FOR MULTIPLE TARGETS AND MODALITIES

Target	Assay Modality
BCMA	Receptor Internalization
BTLA	Signaling
CD137	Signaling
CD200R	Signaling
CD28	Signaling, Bispecific Antibody Development (with PD-1)
CD33	Receptor Internalization
CD47	Ligand-Presenting
CEACAM1	Bispecific Antibody Development (with PD-1)
CTLA4	Signaling, Bispecific Antibody Development (with PD-1 or PD-L1)
FCGR1A	Clustering
FCGR2A	Clustering
FCGR2B	Clustering

Target	Assay Modality
ICOS	Signaling
LAG3	Bispecific Antibody Development (with PD-1 or TIGIT)
OX40	Signaling
PD-1	Signaling (Bioassay & Cell Line), Receptor Dimerization, & Bispecific Antibody Development
PD-L1	Bispecific Antibody Development (with PD-1)
Siglec9	Receptor Internalization
SIRPα	Signaling (Bioassay & Cell Line)
TIGIT	Bispecific Antibody Development (with PD-1 or LAG3)
TIM3	Receptor Dimerization, Bispecific Antibody Development (with PD-L1 or CEACAM1)

CYTOKINE/INTERLEUKIN RECEPTOR DIMERIZATION ASSAYS – BIOASSAYS, EXPRESS KITS, AND CELL LINES FOR MULTIPLE TARGETS

Ligand	Assay Mechanism	Ligand	Assay Mechanism	Ligand	Assay Mechanism
G-CSF	SH2 Recruitment	IL-10	IL-10RA / IL-10RB	IL-26	IL-20R1 / IL-10RB
GM-CSF	CSFR2A / CSFR2B	IL-11	STAT3 Transcriptional Reporter & IL-11R / IL-6ST	IL-27	IL-27RA / IL6ST
M-CSF	CSF1R / CSF1R	IL-12	IL-12RB1 / IL-12RB2	IL-28A	IFNLR1 / IL-10RB
IL-1RN	IκB degradation & IL-1R1 / IL-1RAP	IL-13	IL-4R / IL-13R	IL-28B	IFNLR1 / IL-10RB
IL-1α	IκB degradation & IL-1R1 / IL-1RAP	IL-15	IL-2RB / IL-2RG	IL-29	IFNLR1 / IL-10RB
IL-1β	IκB degradation	IL-17A	IL-17RA / IL-17RC	IL-31	OSMRb / IL-31RA
IL-2	IL-2RB / IL-2RG & IL-2RB / IL-2RG / IL-2RA	IL-17E	IL-17RA / IL-17RB	IL-33	IL-1RL1 (ST2) / IL-1RAP
IL-3	IL-3R / CD131 (CSF2RB)	IL-17F	IL-17RA / IL-17RC	OSM	OSMRb / IL-6ST
IL-4	IL-4R / IL-2RG & IL-4R / IL-13R	IL-18	IL-18R / IL-18RAcP	TNFα	IL-17RD / TNFR2
IL-5	IL-5R / CSF2RB	IL-20	IL-20R1 / IL-20R2	TSLP	IL-7R / TSLP-R
IL-6	IL-6RA / IL-6ST	IL-21	IL-21R / IL-2RG		
IL-7	IL-7R / IL-2RG	IL-22	IL-22R / IL-10RB		
IL-8	CXCR1 & CXCR2 β-Arrestin Recruitment	IL-23	IL-23R / IL-12RB1		
IL-9	IL-9R / IL-2RG	IL-24	IL-20R1 / IL-20R2		

Additional assays for ligands CLCF1, CNTF, CTF1, NP, LIF, IL-14, IL-16, IL-1F10, IL-17B & C, IL-32, IL-34, IL-35, IL-36A, B, C & ET, & IL-37 are available upon request.